MUMBAI, India, July 7 -- Intellectual Property India has published a patent application (202641080395 A) filed by Mohan Babu University on June 30, 2026, for Development And Evaluation Of Imatinib Loaded Nano Cubic Lipid Phase For Anti- Cancer Activity.
Inventors include Dr. S. Varalaxmi; Ms. Rompicherla Kavya; Ms. S. Sushmitha; Ms. S. Raja Rajeswari; and Mr. R. Somanath Siddhartha.
The application for the patent was published on July 03, 2026, under issue no. 27/2026.
Abstract: Cancer Activity This project presents a novel approach to enhancing the therapeutic potential of Imatinib Mesylate, a widely used anticancer drug, through the formulation and evaluation of Imatinib-loaded cubosomes. Cubosomes, owing to their unique nanostructured liquid crystalline phases, offer distinct advantages such as high drug-loading capacity, controlled release, biocompatibility, and stability. In this study, cubosomes were successfully formulated using the emulsification method, integrating key excipients like glyceryl monooleate and Poloxamer 407 to stabilize the system. A series of extensive preformulation and evaluation studies were conducted to ensure the optimal functionality of the cubosomal system. These included: • Solubility studies to determine the suitable lipid and surfactant phases. • Melting point analysis for thermal profiling of raw materials. • Calibration curve generation to enable accurate drug quantification. • FTIR and DSC analyses to confirm drug-excipient compatibility and thermal behaviour. • SEM and TEM imaging to examine cubosomes morphology and confirm nanoscale structure. • Entrapment efficiency studies which revealed high levels of drug loading. • Particle size and zeta potential analysis, essential for stability and in vivo behaviour. • In vitro drug release and dissolution studies to assess release kinetics. • Cell line studies using cancer models to preliminarily evaluate cytotoxicity and therapeutic performance. The innovative aspect of this research lies in the systematic optimization of cubosomal nanocarriers for a poorly soluble anticancer agent, aiming to overcome limitations of conventional delivery methods. The cubosomes demonstrated sustained release behaviour, improved solubility, and potential anticancer efficacy in vitro, marking a significant advancement in nanotechnology-based drug delivery systems. Overall, this project bridges a critical gap between nanocarrier design and cancer therapeutics, positioning Imatinib-loaded cubosomes as a promising platform for future translational research and clinical applications in oncology.
Disclaimer: Curated by HT Syndication.
